Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARCUS CORPMCS · Entity 5078 | Director | May 21, 2026 | May 27, 2026 |
| SteadyMed Ltd.STDY · Entity 163743 | Director · 10% owner | August 30, 2018 | September 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARCUS CORP
Report date May 21, 2026 · Filed May 27, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,206 |
Reported balance
After 2026-05-21 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,391 · Balance 48,206 F1: Granted by Issuer in consideration of service as a director. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.55 · Expires 2026-12-29 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.20 · Expires 2027-12-28 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2027-12-27 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.60 · Expires 2029-12-26 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance 1,000 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.95 · Expires 2031-12-30 | Direct | 750 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance 750 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.25 · Expires 2032-12-29 | Direct | 1,438 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · Balance 1,438 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. F3: Amending solely to correct previously reported Underlying Securities reported in dollars to be reported in shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.69 · Expires 2033-12-28 | Direct | 1,455 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · Balance 1,455 F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted by Issuer in consideration of service as a director.
F2: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan.
F3: Amending solely to correct previously reported Underlying Securities reported in dollars to be reported in shares.
SteadyMed Ltd.
Report date August 30, 2018 · Filed September 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-08-30 · Sale · Disposed 2,937,938 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-08-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-08-30 · Sale · Disposed 1,166,428 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-08-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-08-30 · Sale · Disposed 15,780 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F3: By the Stark Family Trust. The Reporting Person is the trustee of the Stark Family Trust. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2018-08-30 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-08-30 · Sale · Disposed 253,309 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). F4: By Brian Stark and Debra Altshul Stark. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Debra Altshul Stark | 0 |
Reported balance
After 2018-08-30 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2018-08-30 · Sale · Disposed 323,500 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone"). |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2025-08-06 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-08-30 · Other · Disposed 33,350 · Balance 0 F5: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2026-10-05 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-08-30 · Other · Disposed 3,875 · Balance 0 F6: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2027-12-28 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-08-30 · Other · Disposed 21,029 · Balance 0 F6: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2021-08-03 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-08-30 · Other · Disposed 939,428 · Balance 0 F7: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2022-04-24 | Direct | 0 |
Reported balance
After 2018-08-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-08-30 · Other · Disposed 209,650 · Balance 0 F8: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2021-08-03 | IndirectSee Footnote. | 0 |
Reported balance
After 2018-08-30 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-08-30 · Other · Disposed 371,375 · Balance 0 F7: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71. F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. |
| Warrants to Purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2022-04-24 | IndirectSee Footnote. | 0 |
Reported balance
After 2018-08-30 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-08-30 · Other · Disposed 41,875 · Balance 0 F8: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33. F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone").
F2: By Brown Bear Holdings LP. Stark Raving Mad LLC is the GP of the Partnership and the Reporting Person is the sole manager of the GP.
F3: By the Stark Family Trust. The Reporting Person is the trustee of the Stark Family Trust.
F4: By Brian Stark and Debra Altshul Stark.
F5: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.
F6: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.
F7: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2016 was converted into the right to receive $2.71.
F8: Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding warrant to purchase ordinary shares of the Issuer issued in 2017 was converted into the right to receive $2.33.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 25, 2017 Filed Aug 22, 2017 20:17 UTC | SteadyMed Ltd. STDY · Entity 163743 | PurchaseOrdinary Shares | 419,300 | $5.90 | $2,473,870.00 |
DisclosureSEC source: 0001209191-17-049817 · doc4.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,937,938 F1 · balance_after: Reflects the correction of the number of shares beneficially owned from the amounts previously reported in Reporting Person's Section 16 filings. Specifically, the August 4, 2016 Form 4 under reported 5 shares due to a clerical computational error, which error the Reporting Person did not discover until now and so was carried forward in subsequent Forms 4. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 22:48 UTC | MARCUS CORP MCS · Entity 5078 | GrantStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $31.55 | $0.00 |
DisclosureSEC source: 0001140361-16-091250 · doc1.xml · derivative · entry 8 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2026-12-29 F2 · security: Granted pursuant to The Marcus Corporation 2004 Equity and Incentive Awards Plan. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 22:48 UTC | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-091250 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,061 F1 · shares: Restricted stock granted December 29, 2016 vests and becomes exercisable as follows: 50% after 3rd anniversary of the date of the grant and 100% after 5th anniversary of the date of the grant or upon death, disability or retirement. Read SEC document |
| December 29, 2016 Filed Jan 9, 2017 22:38 UTC Amendment | MARCUS CORP MCS · Entity 5078 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001254 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,311 F1 · shares: Restricted stock granted December 29, 2016 vests and becomes exercisable as follows: 50% after 3rd anniversary of the date of grant and 100% after 5th anniversary of the date of grant or upon death, disability or retirement. F2 · shares: The Form 4 filed on December 30, 2016 reported that the reporting person received 1,250 shares. The reporting person actually received 1,500 shares in this transaction. Read SEC document |
| October 05, 2016 Filed Oct 5, 2016 22:19 UTC | SteadyMed Ltd. STDY · Entity 163743 | GrantStock Option (Right to Buy) · Derivative | 3,875 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001209191-16-145120 · doc4.xml · derivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Underlying: Common Stock · 3,875 shares Expires 2026-10-05 F1 · derivative.exercise_date: 1/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested. Read SEC document |
| September 02, 2016 Filed Sep 7, 2016 19:38 UTC | MARCUS CORP MCS · Entity 5078 | GiftCommon Stock | 3,885 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-079080 · doc1.xml · nonDerivative · entry 1 STARK BRIAN JAY · CIK 0001010208 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · As Trustee of Stark Family Trust Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.